Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Aktion Bronchialkarzinom e.V. Hoffmann-La Roche |
---|---|
Information provided by: | Aktion Bronchialkarzinom e.V. |
ClinicalTrials.gov Identifier: | NCT00536640 |
This study wants to determine the activity of a non chemotherapy first line biological treatment with Erlotinib/Bevacizumab or Gemcitabine-Cisplatin/Bevacizumab in patients with the diagnosis of non-squamous advanced Non Small Lung Cancer.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Non-Small-Cell Lung |
Drug: Erlotinib Drug: Bevacizumab Drug: Gemcitabine Drug: Cisplatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabin/Cisplatin Plus Bevacizumab |
Estimated Enrollment: | 220 |
Study Start Date: | November 2007 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: Erlotinib
150 mg per os, given daily until tumor progression
Drug: Bevacizumab
15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
|
2: Active Comparator |
Drug: Bevacizumab
15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
Drug: Gemcitabine
1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
Drug: Cisplatin
80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
|
Prospective, randomized multi-center, open label phase II study to determine the activity of a non-chemotherapy first line biological treatment with Erlotinib/Bevacizumab or Gemcitabine-Cisplatin/Bevacizumab in patients with the diagnosis of non-squamous advanced Non-Small-Lung-Cancer.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
The following histological tumor types are eligible:
Adequate hematological laboratory parameters
Adequate hepatic laboratory parameters
Adequate renal laboratory parameters
Exclusion Criteria:
Any radiotherapy with exception of the following situations:
Patients with any clinically significant disease that in the opinion of the investigator is likely to put the patient at risk or to interfere with the evaluation of the patient's safety and of the study outcome. This includes, but is not limited to:
Contact: Prof. Dr. Martin Wolf, Study Principal Investigator | +49 (0)561 9803046 | mwolf@klinikum-kassel.de |
Contact: Thomas Acker, Philipps University Marburg | +49 (0)6421 28 66 513 | thomas.acker@kks.uni-marburg.de |
Germany | |
Klinikum Kassel GmbH | Recruiting |
Kassel, Germany, 34125 | |
Contact: Prof. Dr. Martin Wolf, MD ++49 (0)561 980 30 46 mwolf@klinikum-kassel.de | |
Klinik Löwenstein | Recruiting |
Löwenstein, Germany, 74245 | |
Fachklinik für Lungenerkrankungen Immenhausen | Recruiting |
Immenhausen, Germany, D-34376 | |
Augusta-Krankenanstalten | Recruiting |
Bochum, Germany, D-44791 | |
Asklepios Klinik Harburg | Recruiting |
Hamburg, Germany, D-21075 | |
Städtische Kliniken Bielefeld | Not yet recruiting |
Bielefeld, Germany, D-33604 | |
Gemeinschaftskrankenhaus Havelhöhe | Recruiting |
Berlin, Germany, D-14089 | |
Klinikum Lippe-Lemgo | Recruiting |
Lemgo, Germany, D-32657 | |
Diakoniekrankenhaus Halle/S. | Recruiting |
Halle, Germany, D-06114 | |
Medizinisches Versorgungszentrum Osthessen | Recruiting |
Fulda, Germany, D-36043 | |
Klinikum Ludwigshafen | Recruiting |
Ludwigshafen, Germany, D-67063 | |
Krankenhaus Nordwest | Recruiting |
Frankfurt am Main, Germany, D-60488 | |
Johanniter-Krankenhaus Bonn | Recruiting |
Bonn, Germany, D-53113 | |
Klinikum Frankfurt (Oder)GmbH | Recruiting |
Frankfurt Oder, Germany, D-15232 | |
St. Vincentius-Kliniken Karlsruhe | Recruiting |
Karlsruhe, Germany, D-76137 | |
Forschungszentrum Borstel | Recruiting |
Borstel, Germany, D-23845 | |
Onkologische Schwerpunktpraxis Dr. Lothar Müller | Recruiting |
Leer, Germany, D-26789 | |
Universitätsklinikum Marburg | Recruiting |
Marburg, Germany, D-35033 | |
St. Vincenz Krankenhaus | Not yet recruiting |
Limburg, Germany, D-65549 | |
Onkologische Gemeinschaftspraxis Dr. Nusch | Recruiting |
Velbert, Germany, D-42551 | |
Oncologianova GmbH | Not yet recruiting |
Recklinghausen, Germany, D-45657 | |
Johaniter Krankenhaus Rheinhausen | Not yet recruiting |
Duisburg, Germany, D-47228 | |
Lungenklinik Hemer | Not yet recruiting |
Hemer, Germany, 58675 | |
Krankenhaus Großhansdorf | Recruiting |
Großhansdorf, Germany, D-22927 | |
St. Johannes Hospital | Not yet recruiting |
Duisburg, Germany, D-47166 | |
Helios Klinikum Emil v. Behring | Recruiting |
Berlin, Germany, D-14165 | |
Krankenhaus Barmherzige Brüder | Recruiting |
Regensburg, Germany, D-93049 | |
Thoraxklinik Universitätsklinikum Heidelberg | Recruiting |
Heidelberg, Germany, D-69126 | |
Malteser Krankenhaus St. Hildegardis | Recruiting |
Köln, Germany, D-50931 | |
Charite´ Mitte | Recruiting |
Berlin, Germany, D-10117 | |
Katholisches Klinikum Haus Marienhof | Not yet recruiting |
Koblenz, Germany, 56073 | |
Universitätsklinikum Schleswig-Holstein | Recruiting |
Lübeck, Germany, D-23538 | |
Städtisches Krankenhaus Frankfurt-Höchst | Recruiting |
Frankfurt, Germany, D-65929 | |
Universitätsklinikum Greifswald | Recruiting |
Greifswald, Germany, D-17487 | |
Pius Hospital Oldenburg | Not yet recruiting |
Oldenburg, Germany, D-26121 | |
Hanse-Klinikum Stralsund | Recruiting |
Stralsund, Germany, D-18410 | |
Onkologische Schwerpunktpraxis Dr. Neise | Not yet recruiting |
Krefeld, Germany, D-47798 | |
Georg-August-Universität Göttingen | Not yet recruiting |
Göttingen, Germany, D-37075 | |
Klinikum Bayreuth GmbH | Recruiting |
Bayreuth, Germany, D-95445 | |
Universitätsklinikum Rostock | Not yet recruiting |
Rostock, Germany, D-18055 | |
St. Hildegardis Krankenhaus | Recruiting |
Mainz, Germany, D-55131 | |
Fachkliniken Wangen | Recruiting |
Wangen, Germany, D-88239 | |
Klinikum der Universität München | Not yet recruiting |
München, Germany, D-80336 | |
Helios Klinikum Wuppertal | Recruiting |
Wuppertal, Germany, D-42283 |
Principal Investigator: | Prof. Dr. Martin Wolf, MD | Aktion Bronchialkarzinom e.V. |
Responsible Party: | Aktion Bronchialkarzinom ( Prof. Dr. med. Martin Wolf ) |
Study ID Numbers: | ABC-2006-NSCLC-01 |
Study First Received: | September 27, 2007 |
Last Updated: | February 5, 2009 |
ClinicalTrials.gov Identifier: | NCT00536640 History of Changes |
Health Authority: | Germany: Paul-Ehrlich-Institut |
Non Small Cell Lung Carcinoma (NSCLC Stage III an IV) |
Antimetabolites Thoracic Neoplasms Erlotinib Immunologic Factors Bevacizumab Protein Kinase Inhibitors Angiogenesis Inhibitors Immunosuppressive Agents Antiviral Agents Carcinoma |
Respiratory Tract Diseases Cisplatin Radiation-Sensitizing Agents Lung Neoplasms Lung Diseases Non-small Cell Lung Cancer Gemcitabine Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |
Thoracic Neoplasms Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Bevacizumab Protein Kinase Inhibitors Neoplasms by Site Respiratory Tract Diseases Cisplatin Lung Neoplasms Therapeutic Uses |
Growth Inhibitors Angiogenesis Modulating Agents Gemcitabine Erlotinib Respiratory Tract Neoplasms Neoplasms by Histologic Type Growth Substances Enzyme Inhibitors Angiogenesis Inhibitors Immunosuppressive Agents Antiviral Agents Pharmacologic Actions Carcinoma Neoplasms Radiation-Sensitizing Agents |